orforglipron semaglutide comparison In a phase III trial, yielded better HbA1c reduction compared with oral at 52 weeks. Gastrointestinal side effects were more common with orforglipron, leading to more treatment discontinuations. Read more Orforglipron FDA Approved April 2026:

All medications have side effects, and the anti-obesity drugs are no exception, says Christopher McGowan, MD, a gastroenterologist, obesity medicine specialist, and founder of True You Weight Loss

Many patients feel fuller for longer on Mounjaro treatment, which can enhance adherence

When integrating Brain Ritual with ashwagandha or something similar, timing becomes crucial

Tirzepatide is an innovative medication that targets both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors

This is the first study demonstrating that metformin can reduce oxidative stress through its mitochondrial action

As our mechanistic understanding deepens and therapeutic applications broaden, GLP-1R agonists are poised to become cornerstone agents in the prevention and management of cardiometabolic diseases, ultimately improving patient outcomes and public health